Veracyte | VCYT - Cost Of Sales


Veracyte reported $42.19M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Agenus USD 642K 399K Sep/2025
Agilent USD 845M 7M Mar/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
Bruker USD 422.5M 21.1M Jun/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Illumina USD 389M 19M Jun/2026
Intrexon USD 1.01M 344K Jun/2024
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
Laboratory Of America USD 2.7B 97.8M Jun/2026
Ligand Pharmaceuticals USD 11.31M 59K Jun/2026
Myriad Genetics USD 63M 1.1M Dec/2025
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Roche Holding CHF 7.85B 630M Jun/2026
Sangamo BioSciences 2.42M 1.11M Jun/2024
Siemens EUR 12.29B 218M Jun/2026
Sonic Healthcare AUD 751.66M 801.13M Dec/2024
Thermo Fisher Scientific USD 7.54B 577M Jun/2026
Veracyte USD 42.19M 3.7M Jun/2026
Waters USD 1.16B 430M Jun/2026